Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
Michelle N. Rheault, Charles E. Alpers, Jonathan Barratt, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 26, pp. 2436-2445
Closed Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Autoantibodies Targeting Nephrin in Podocytopathies
Felicitas E. Hengel, Silke Dehde, Moritz Lassé, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 5, pp. 422-433
Closed Access | Times Cited: 86
The role of endothelin receptor antagonists in kidney disease
Xiaoting Ma, Yanhu Liang, Wen‐Ming Chen, et al.
Renal Failure (2025) Vol. 47, Iss. 1
Open Access | Times Cited: 2
Podocyte-targeted therapies — progress and future directions
Kristin Meliambro, John Cijiang He, Kirk N. Campbell
Nature Reviews Nephrology (2024) Vol. 20, Iss. 10, pp. 643-658
Closed Access | Times Cited: 16
Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group
Şafak Mirioğlu, Lisa Daniel-Fischer, İlay Berke, et al.
Nephrology Dialysis Transplantation (2024) Vol. 39, Iss. 4, pp. 569-580
Open Access | Times Cited: 15
Risk-directed management of chronic kidney disease
Matthew F. Blum, Brendon L. Neuen, Morgan E. Grams
Nature Reviews Nephrology (2025)
Closed Access | Times Cited: 1
Advances in Focal Segmental Glomerulosclerosis Treatment From the Perspective of the Newest Mechanisms of Podocyte Injury
Yan Zhu, Gaosi Xu
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 857-875
Open Access | Times Cited: 1
Drug Development in Pediatric Chronic Kidney Disease: A Review of Promising Treatments, Old Challenges, and New Strategies
Alexander J. Kula
Pediatric Drugs (2025)
Closed Access | Times Cited: 1
Endothelin System in Hypertension and Chronic Kidney Disease
Ernesto L. Schiffrin, David M. Pollock
Hypertension (2023) Vol. 81, Iss. 4, pp. 691-701
Closed Access | Times Cited: 20
Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy
Howard Trachtman, Radko Komers, Jula K. Inrig
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 6, pp. 571-576
Open Access | Times Cited: 7
Improving Kidney Disease Care: One Giant Leap for Nephrology
Michele Provenzano, Lilio Hu, Edoardo Tringali, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 828-828
Open Access | Times Cited: 7
Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety
Kirk N. Campbell, Loreto Gesualdo, Edward Murphy, et al.
Kidney Medicine (2024) Vol. 6, Iss. 6, pp. 100833-100833
Open Access | Times Cited: 7
Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease
Donald E. Kohan, Patricia W. Bedard, Celia Jenkinson, et al.
Clinical Science (2024) Vol. 138, Iss. 11, pp. 645-662
Open Access | Times Cited: 7
Drug repurposing for glomerular diseases: an underutilized resource
Monica Suet Ying Ng, Gursimran Kaur, Ross S. Francis, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 11, pp. 707-721
Closed Access | Times Cited: 6
Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease
Vanja Ivković, Annette Bruchfeld
Clinical Kidney Journal (2024) Vol. 17, Iss. 4
Open Access | Times Cited: 5
Endothelin Inhibitors in Chronic Kidney Disease: New Treatment Prospects
Agata Rakotoarison, Marta Kepinská, Andrzej Konieczny, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 20, pp. 6056-6056
Open Access | Times Cited: 4
Syndromes néphrotiques idiopathiques : prise en charge thérapeutique spécifique chez l’adulte
V. Audard, Antoine Morel, J. Oniszcuk, et al.
Encyclopédie médico-chirurgicale. Néphrologie (2025) Vol. 37, Iss. 1, pp. 1-10
Closed Access
Pathogenesis of Focal Segmental Glomerulosclerosis and Related Disorders
Mehmet M. Altintas, Shivangi Agarwal, Yashwanth R. Sudhini, et al.
Annual Review of Pathology Mechanisms of Disease (2025) Vol. 20, Iss. 1, pp. 329-353
Closed Access
From Gene to Clinic: The Role of APOL1 in Focal Segmental Glomerulosclerosis
Charlotte Delrue, Marijn M. Speeckaert
Sclerosis (2025) Vol. 3, Iss. 1, pp. 6-6
Open Access
Sparsentan clinical trials in glomerular diseases: defining endpoints and a path forward in light of the parasol initiative
Howard Trachtman, Jula K. Inrig, Radko Komers
Future Rare Diseases (2025) Vol. 5, Iss. 1
Open Access
Advances and challenges in kidney fibrosis therapeutics
Lilia Abbad, Emmanuel Estève, Christos Chatziantoniou
Nature Reviews Nephrology (2025)
Closed Access
Indications for genetic testing in adults with focal segmental glomerulosclerosis
Melissa Pilco Teran, Amir Shabaka, Mónica Furlano, et al.
Nefrología (English Edition) (2025)
Open Access
Real-world assessment of sparsentan’s drug safety framework
Wenjing Fu, Jingyu Wang, Yuzhou Xue, et al.
Renal Failure (2025) Vol. 47, Iss. 1
Open Access
Framework for precision medicine in focal segmental glomerulosclerosis: Translation of sparsentan-responsive genes in a rat model to kidney disease associated proteins in biofluids
Sean Eddy, Viji Nair, John R. Hartman, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Research trends and performance of endothelin A receptor antagonist in kidney care: a bibliometric analysis
Wisit Cheungpasitporn, Pajaree Krisanapan, Supawadee Suppadungsuk, et al.
Renal Failure (2025) Vol. 47, Iss. 1
Open Access
Emerging pharmacotherapies for the treatment of childhood nephrotic syndrome
Eloise Salmon, Howard Trachtman
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Page 1 - Next Page

Scroll to top